T 3139/19 (Solid kidney tumours/NOVARTIS) of 29.07.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T313919.20210729
- Date of decision
- 29 July 2021
- Case number
- T 3139/19
- Petition for review of
- -
- Application number
- 10174985.1
- IPC class
- A61K 45/06A61K 31/337A61K 31/5685A61K 31/555A61K 31/7068A61K 31/704A61P 35/00A61K 31/436A61K 31/502A61K 31/475
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Treatment of solid kidney tumours with a rapamycin derivative
- Applicant name
- Novartis Pharma AG
- Opponent name
- Synthon Biopharmaceuticals B.V.
Fresenius Kabi Deutschland GmbH
KRKA, d.d., Novo mesto
Teva Pharmaceutical Industries Ltd
STADA Arzneimittel AG
Wittkopp, Alexander
Generics [UK] Ltd
Intas Pharmaceuticals Ltd. - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 76(1)
- Keywords
- Subject-matter extends beyond content of earlier application (yes) - all requests
- Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.